Clinical Trials at Mercy Oncology and Hematology - Clayton-Clarkson
As of September 2026, 33 paid clinical trials are recruiting at Mercy Oncology and Hematology - Clayton-Clarkson, located at Mercy Oncology and Hematology - Clayton-Clarkson, 15945 Clayton Rd Suite 120, Ballwin, MO 63011, phone (636) 256-5000 in Ballwin, Missouri. Active studies at this site cover conditions such as Anatomic Stage II Breast Cancer AJCC v8, Malignant Solid Neoplasm and Anatomic Stage IIIA Breast Cancer AJCC v8. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
33 clinical trials at Mercy Oncology and Hematology - Clayton-Clarkson
·Clear filters·Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Family Communications After Genetic Testing
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Common conditions studied in Ballwin
- Anatomic Stage II Breast Cancer AJCC v8 (5 active studies)
- Malignant Solid Neoplasm (4 active studies)
- Anatomic Stage IIIA Breast Cancer AJCC v8 (3 active studies)
- Lung Non-Small Cell Carcinoma (3 active studies)
- Anatomic Stage I Breast Cancer AJCC v8 (2 active studies)
- Anatomic Stage IIIB Breast Cancer AJCC v8 (2 active studies)
Leading research sponsors in Ballwin
- Alliance for Clinical Trials in Oncology
- SWOG Cancer Research Network
- National Cancer Institute (NCI)
- NRG Oncology
- ECOG-ACRIN Cancer Research Group
Frequently asked questions
How many paid clinical trials are currently recruiting in Ballwin?
There are approximately 38 recruiting clinical trials in Ballwin, Missouri listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Ballwin pay participants?
Most recruiting trials in Ballwin compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Ballwin?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Ballwin?
The most common conditions under active study in Ballwin include Anatomic Stage II Breast Cancer AJCC v8 (5), Malignant Solid Neoplasm (4), Anatomic Stage IIIA Breast Cancer AJCC v8 (3), Lung Non-Small Cell Carcinoma (3), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Ballwin?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Ballwin on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Ballwin?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Ballwin?
Recruiting research sites in Ballwin include Mercy Oncology and Hematology - Clayton-Clarkson, Saint Louis Cancer and Breast Institute-Ballwin, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Ballwin right now?
The largest active categories in Ballwin are Cancer & tumors (31), Mental health & behavior (1). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Mercy Oncology and Hematology - Clayton-Clarkson?
Mercy Oncology and Hematology - Clayton-Clarkson is located at Mercy Oncology and Hematology - Clayton-Clarkson, 15945 Clayton Rd Suite 120, Ballwin, MO 63011. Use the Google Maps link in the intro above to get directions.
How do I contact Mercy Oncology and Hematology - Clayton-Clarkson?
You can reach Mercy Oncology and Hematology - Clayton-Clarkson by phone at (636) 256-5000. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.